Literature DB >> 34817712

The Evolving Classification of Diffuse Gliomas: World Health Organization Updates for 2021.

Alejandro Perez1, Jason T Huse2.   

Abstract

PURPOSE OF REVIEW: The upcoming 2021 World Health Organization (WHO) Classification of Tumours of the Central Nervous System will feature numerous changes in classification, diagnostic criteria, nomenclature, and grading of diffuse gliomas. This article reviews these changes and the clinical and molecular findings underlying them. RECENT
FINDINGS: Since the publication of the 2016 World Health Organization (WHO) Classification of Tumours of the Central Nervous System, research has led to new insights into how molecular changes impact both the classification and grading of CNS tumors. The continued integration of molecular and histopathological features has led to changes in diagnostic criteria and grading for various tumors. In the new 2021 WHO CNS tumor classification scheme, diffuse gliomas will be classified as either adult-type diffuse gliomas, pediatric-type diffuse high-grade gliomas, or pediatric-type diffuse low-grade gliomas. The upcoming changes in the classification of adult-type and pediatric-type diffuse gliomas allow for more effective communication of both diagnostic and prognostic information, and-particularly in the case of pediatric-type diffuse gliomas-may suggest possible targeted strategies for therapeutic intervention.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Adult; Diffuse glioma; Genomics; Molecular; Pediatric; World Health Organization

Mesh:

Year:  2021        PMID: 34817712     DOI: 10.1007/s11910-021-01153-8

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  23 in total

1.  The somatic genomic landscape of glioblastoma.

Authors:  Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

2.  CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.

Authors:  Gerald F Reis; Melike Pekmezci; Helen M Hansen; Terri Rice; Roxanne E Marshall; Annette M Molinaro; Joanna J Phillips; Hannes Vogel; John K Wiencke; Margaret R Wrensch; Kyle M Walsh; Arie Perry
Journal:  J Neuropathol Exp Neurol       Date:  2015-05       Impact factor: 3.685

3.  cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant.

Authors:  David N Louis; Caterina Giannini; David Capper; Werner Paulus; Dominique Figarella-Branger; M Beatriz Lopes; Tracy T Batchelor; J Gregory Cairncross; Martin van den Bent; Wolfgang Wick; Pieter Wesseling
Journal:  Acta Neuropathol       Date:  2018-03-01       Impact factor: 17.088

4.  cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.

Authors:  Daniel J Brat; Kenneth Aldape; Howard Colman; Dominique Figrarella-Branger; Gregory N Fuller; Caterina Giannini; Eric C Holland; Robert B Jenkins; Bette Kleinschmidt-DeMasters; Takashi Komori; Johan M Kros; David N Louis; Catriona McLean; Arie Perry; Guido Reifenberger; Chitra Sarkar; Roger Stupp; Martin J van den Bent; Andreas von Deimling; Michael Weller
Journal:  Acta Neuropathol       Date:  2020-01-29       Impact factor: 17.088

5.  cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading.

Authors:  David N Louis; Pieter Wesseling; Kenneth Aldape; Daniel J Brat; David Capper; Ian A Cree; Charles Eberhart; Dominique Figarella-Branger; Maryam Fouladi; Gregory N Fuller; Caterina Giannini; Christine Haberler; Cynthia Hawkins; Takashi Komori; Johan M Kros; H K Ng; Brent A Orr; Sung-Hye Park; Werner Paulus; Arie Perry; Torsten Pietsch; Guido Reifenberger; Marc Rosenblum; Brian Rous; Felix Sahm; Chitra Sarkar; David A Solomon; Uri Tabori; Martin J van den Bent; Andreas von Deimling; Michael Weller; Valerie A White; David W Ellison
Journal:  Brain Pathol       Date:  2020-04-19       Impact factor: 6.508

6.  cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".

Authors:  Daniel J Brat; Kenneth Aldape; Howard Colman; Eric C Holland; David N Louis; Robert B Jenkins; B K Kleinschmidt-DeMasters; Arie Perry; Guido Reifenberger; Roger Stupp; Andreas von Deimling; Michael Weller
Journal:  Acta Neuropathol       Date:  2018-09-26       Impact factor: 17.088

7.  Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.

Authors:  Kosuke Aoki; Hideo Nakamura; Hiromichi Suzuki; Keitaro Matsuo; Keisuke Kataoka; Teppei Shimamura; Kazuya Motomura; Fumiharu Ohka; Satoshi Shiina; Takashi Yamamoto; Yasunobu Nagata; Tetsuichi Yoshizato; Masahiro Mizoguchi; Tatsuya Abe; Yasutomo Momii; Yoshihiro Muragaki; Reiko Watanabe; Ichiro Ito; Masashi Sanada; Hironori Yajima; Naoya Morita; Ichiro Takeuchi; Satoru Miyano; Toshihiko Wakabayashi; Seishi Ogawa; Atsushi Natsume
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

8.  Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.

Authors:  Gang Wu; Alberto Broniscer; Troy A McEachron; Charles Lu; Barbara S Paugh; Jared Becksfort; Chunxu Qu; Li Ding; Robert Huether; Matthew Parker; Junyuan Zhang; Amar Gajjar; Michael A Dyer; Charles G Mullighan; Richard J Gilbertson; Elaine R Mardis; Richard K Wilson; James R Downing; David W Ellison; Jinghui Zhang; Suzanne J Baker
Journal:  Nat Genet       Date:  2012-01-29       Impact factor: 38.330

9.  CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.

Authors:  Romain Appay; Caroline Dehais; Claude-Alain Maurage; Agusti Alentorn; Catherine Carpentier; Carole Colin; François Ducray; Fabienne Escande; Ahmed Idbaih; Aurélie Kamoun; Yannick Marie; Karima Mokhtari; Emeline Tabouret; Nesrine Trabelsi; Emmanuelle Uro-Coste; Jean-Yves Delattre; Dominique Figarella-Branger
Journal:  Neuro Oncol       Date:  2019-12-17       Impact factor: 13.029

10.  Infratentorial IDH-mutant astrocytoma is a distinct subtype.

Authors:  Rouzbeh Banan; Damian Stichel; Anja Bleck; Bujung Hong; Ulrich Lehmann; Abigail Suwala; Annekathrin Reinhardt; Daniel Schrimpf; Rolf Buslei; Christine Stadelmann; Karoline Ehlert; Marco Prinz; Till Acker; Jens Schittenhelm; David Kaul; Leonille Schweizer; David Capper; Patrick N Harter; Nima Etminan; David T W Jones; Stefan M Pfister; Christel Herold-Mende; Wolfgang Wick; Felix Sahm; Andreas von Deimling; Christian Hartmann; David E Reuss
Journal:  Acta Neuropathol       Date:  2020-08-10       Impact factor: 15.887

View more
  4 in total

1.  Pediatric high-grade gliomas and the WHO CNS Tumor Classification-Perspectives of pediatric neuro-oncologists and neuropathologists in light of recent updates.

Authors:  Gerrit H Gielen; Joshua N Baugh; Dannis G van Vuurden; Sophie E M Veldhuijzen van Zanten; Darren Hargrave; Maura Massimino; Veronica Biassoni; Andres Morales la Madrid; Michael Karremann; Maria Wiese; Ulrich Thomale; Geert O Janssens; André O von Bueren; Thomas Perwein; Gunther Nussbaumer; Eelco W Hoving; Pitt Niehusmann; Marco Gessi; Robert Kwiecien; Simon Bailey; Torsten Pietsch; Felipe Andreiuolo; Christof M Kramm
Journal:  Neurooncol Adv       Date:  2022-05-20

2.  The Value of H2BC12 for Predicting Poor Survival Outcomes in Patients With WHO Grade II and III Gliomas.

Authors:  Jie Zhou; Zhaoquan Xing; Yilei Xiao; Mengyou Li; Xin Li; Ding Wang; Zhaogang Dong
Journal:  Front Mol Biosci       Date:  2022-04-25

3.  Systematic transcriptome profiling of pyroptosis related signature for predicting prognosis and immune landscape in lower grade glioma.

Authors:  Huihan Yu; Meiting Gong; Jian Qi; Chenggang Zhao; Wanxiang Niu; Suling Sun; Shuyang Li; Bo Hong; Junchao Qian; Hongzhi Wang; Xueran Chen; Zhiyou Fang
Journal:  BMC Cancer       Date:  2022-08-13       Impact factor: 4.638

4.  Diffuse low-grade glioma misdiagnosed as acute cerebral infarction: A case report.

Authors:  Yipo Ma; Jinfeng Zhang; Ying Wen; Jinghua Chen; Lei Yuan; Xuechun Jiang; Dan Xu; Kefu Liu
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.